Two-Component Liposomal Adjuvant B is a liposomal adjuvant system based on 3-O-deacylated-4'-monophosphoryl lipid A (3D-MPLA) and Quillaja saponin QS-21 fraction. It achieves synergistic delivery of the two adjuvants via bilayer liposomes, effectively enhancing immune responses and vaccine efficacy.Prepared by the thin-film dispersion method combined with liposome extrusion technology, the liposomes feature uniform particle size (PDI < 0.2) ranging from 95 nm to 120 nm. It is a ready-to-use solution appearing as an opalescent, colorless to light brown liquid, which can be directly mixed with antigens (suitable for reconstitution of lyophilized vaccines).
II. Technical Parameters
| Item | Specification |
| Components | 3D-MPLA + QS-21 fraction |
| Particle size distribution | 80–120 nm (PDI < 0.2) |
| pH value | 5.8–6.4 |
| Shelf life | 2 years (stored at 2–8 °C, protected from light |
Figure 1 Schematic diagram of particle size results
| Item | Average | Standard Deviation | Relative Standard Deviation | Minimum | Maximum |
| Z-Average (nm) | 100.8
| - | -
| 100.8
| 100.8
|
| Polydispersity Index (PI) | 0.02836
| -
| -
| 0.02836
| 0.02836
|
| Area Mean Diameter of Volume-weighted Distribution (nm) | 106.2
| -
| -
| 106.2
| 106.2
|
| Intercept | 0.9801
| -
| -
| 0.9801
| 0.9801
|
| Polydispersity | 0.001341
| -
| -
| 0.001341
| 0.001341 |
Figure 2 Transmission electron microscopy (TEM) image
III. Product Information
1. ComponentsCore raw materials consist of 3D-MPLA produced by fermentation of Salmonella minnesota R595 and QS-21 fraction (purity ≥95%) extracted from Quillaja saponaria. All materials comply with the adjuvant technical guidelines of NMPA.
2. Manufacturing and TestingEach component is tested to meet strict internal standards, including component identification and batch consistency.The adjuvant is manufactured in a GMP-grade cleanroom via a tightly controlled liposome production process, with batch-to-batch consistency CV < 5%.Sterility is ensured by 0.22 μm sterile filtration during production. Stability is verified by accelerated testing (25 °C / 75% RH, 6 months), with active ingredient retention >95% and particle size variation <10%.
3. Immune ResponseThe adjuvant activates the immune system through dual TLR4/TRIF and CD2 pathways.The MPL component activates TRIF signaling via the TLR4/MD-2 receptor, inducing dendritic cell maturation and promoting IL-12 secretion. Meanwhile, the QS-21 fraction directly activates ZAP-70 kinase by binding to the CD2 receptor on T cells, enhancing IFN-γ production.In addition, the liposomal carrier significantly improves the uptake efficiency of antigen-presenting cells (APCs), thereby synergistically eliciting robust humoral and cellular immune responses.
4. Verified Application ScenariosHerpes zoster vaccine; RSV vaccine; Malaria vaccine
5. Compatibility Ratios of Different Antigens with Two-Component Liposomal Adjuvant B
| Vaccine Type | Antigen | Antigen : Two-Component Liposomal Adjuvant B |
| Recombinant zoster vaccine | gE protein | 50 μg : 50 μg (1:1) |
| Malaria vaccine | RST, S | 25 μg : 25 μg (1:1) |
| HIV vaccine | gp120 protein | 20–50 μg : 50 μg (0.5~1:1) |
| RSV vaccine | Pre F3 | 50 μg : 50 μg (1:1) |
Note: The concentration of Two-Component Liposomal Adjuvant B is 100 μg/mL.
6. Recommended Dosage
Recommended injection volume of antigen/adjuvant mixture at different administration sites in laboratory animals
| Species | Dosage |
| Mouse | 50 μL |
| Rat | 100 μL |
| Guinea pig | 200 μL |
| Rabbit | 200 μL |
| Human | 500 μL |
ZJ26F0535258